MDH2 silencing reduces prostate cancer cell growth and enhances docetaxel sensitivity by causing metabolic inefficiency; high MDH2 expression is associated with shorter recurrence-free survival and treatment tolerance in prostate cancer patients [22]. Here, MDH2 is linked to prostate carcinoma.